Advertisement
Screener

MEDICINOVA, INC. (MNOV) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

1.3 / 5 stars · 10/40 Roast Me

MEDICINOVA, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

MEDICINOVA, INC. (MNOV) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$3.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets

us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-10

  • MEDICINOVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$3.40M, a 440.00% decline from fiscal 2024.
  • MEDICINOVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $1.00M, a 0.00% change from fiscal 2023.
  • MEDICINOVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $1.00M, a 72.97% decline from fiscal 2022.
  • MEDICINOVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $3.70M, a 825.00% increase from fiscal 2021.
Period endValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month
2025-12-31-$3.40M
10-K · filed 2026-03-10
2024-12-31$1.00M
10-K · filed 2025-02-19
2023-12-31$1.00M
10-K · filed 2024-02-15
2022-12-31$3.70M
10-K/A · filed 2023-03-28
2021-12-31$400.00K
10-K · filed 2022-02-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
Atrium Therapeutics, Inc. (RNA)United States$0.140B